Sequence specific antimicrobials
AssigneeThe Rockefeller University
InventorsDavid Bikard, Luciano Marraffini
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
Claims21
A pharmaceutical composition for selectively killing targeted bacteria in a subject comprising a pharmaceutically acceptable carrier and a clustered regularly interspaced short palindromic repeats (CRISPR) system, wherein the CRISPR system comprises DNA encoding:
- i) a Type I, Type II, or Type III CRISPR-associated enzyme;
- and
- ii) a targeting RNA that targets at least one bacterial chromosome at a target site in the bacteria of the subject for selective killing of the targeted bacteria.
A pharmaceutical composition for selectively killing targeted bacteria in a subject comprising a pharmaceutically acceptable carrier and a clustered regularly interspaced short palindromic repeats (CRISPR) system, wherein the CRISPR system comprises DNA encoding:
- i) a Type I, Type II, or Type III CRISPR-associated enzyme;
- and
- ii) a targeting RNA that targets an antibiotic resistance gene on a bacterial plasmid at a target site within the bacterial plasmid in the bacteria of the subject for selective killing of the targeted bacteria in the presence of the antibiotic.
A pharmaceutical composition for selectively killing targeted bacteria in a subject comprising a pharmaceutically acceptable carrier and a clustered regularly interspaced short palindromic repeats (CRISPR) system, wherein the CRISPR system comprises DNA encoding:
- i) a Type I, Type II, or Type III CRISPR-associated enzyme;
- and
- ii) a targeting RNA that targets a bacterial plasmid comprising an antibiotic resistance gene at a target site within the bacterial plasmid in the bacteria of the subject for selective killing of the targeted bacteria in the presence of the antibiotic.
Dependencies are inferred from the claim text.